Interní Med. 2017; 19(4): 225-229 | DOI: 10.36290/int.2017.035

Hospital-acquired pneumonia – optimal settings of the initial empirical antibiotic therapy

MUDr. Radovan Uvízl, Ph.D.1, MUDr. Tomáš Herkeľ1, prof. MUDr. Milan Kolář, Ph.D.2 a pracovní skupina
1 1Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Olomouc
a Lékařská fakulta Univerzity Palackého v Olomouci
2 2Ústav mikrobiologie, Fakultní nemocnice Olomouc a Lékařská fakulta Univerzity Palackého v Olomouci
Pracovní skupina: MUDr. Miroslava Htoutou Sedláková, doc. MUDr. Milan Adamus, Ph.D., MBA, MUDr. Lenka Doubravská,
doc. MUDr. Tomáš Gabrhelík, Ph.D., Mgr. Vendula Pudová, Ph.D., MUDr. Kateřina Langová, doc. MUDr. Roman Zazula, Ph.D.,
MUDr. Tomáš Řezáč, MUDr. Michal Moravec, doc. MUDr. Pavel Čermák, CSc., prof. MUDr. Pavel Ševčík, CSc., MUDr. Jan Stašek,
MUDr. Alena Ševčíková, MUDr. Markéta Hanslianová, MUDr. Zdeněk Turek, prof. MUDr. Vladimír Černý, Ph.D., MUDr. Pavla Paterová

Hospital-acquired pneumonia (HAP) is one of the most severe complications occurring in patients during their hospital stayand an important factor affecting the economy of health care; it is often associated with bacterial resistance. The presence ofindividual etiological pathogens causing HAP and their resistance to antimicrobial agents play a key role in the selection of adequateantibiotic therapy. However, not knowing these pathogens usually complicates causative antibiotic therapy at the onsetof pneumonia. It takes hours to days to identify them and, in the meantime, empirical antibiotic therapy must be initiated. Theusual pathogens causing HAP are endogenous bacterial strains originating from the primary microflora in early-onset HAP andsecondary colonizing bacteria with a higher level of resistance in late-onset HAP. The onset of HAP is often manifested by clinicalsigns of sepsis and considerably worsens the prognosis of patients. Therefore, the aims were to obtain current epidemiologicaldata on pathogens causing HAP and to determine their susceptibility to antibiotics. The results were compared with data froma protocol for reference initial empirical antibiotic therapy of HAP so that optimal initial antibiotic therapy of HAP could be set.

Keywords: nosocomial infections, HAP, initial empirical antibiotic therapy, pneumonia

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Uvízl R, Herkeľ T, Kolář M. Hospital-acquired pneumonia – optimal settings of the initial empirical antibiotic therapy. Interní Med. 2017;19(4):225-229. doi: 10.36290/int.2017.035.
Download citation

References

  1. Joseph NM, Sistla S, Dutta TK, et al. Ventilator-associated pneumonia: a review. Eur J Intern Med, 2010; 21: 360-368. Go to original source... Go to PubMed...
  2. Jones RN. Microbial etiologies of hospital-acquired pneumonia and ventilator-associated bacterial pneumonia. Clin Index Dis., 2010; 51(1 Suppl): 81-87. Go to original source... Go to PubMed...
  3. Vincent JL, Bihar, DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA, 1995; 23-30, 274(8): 639-644. Go to original source...
  4. Uvizl R, Hanulik V, Husickova V, et al. Hospital-acquired pneumonia in ICU patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub., 2011; 155(4): 373-378. Go to original source... Go to PubMed...
  5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005; 171: 388. Go to original source...
  6. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am, 2004; 18: 939. Go to original source... Go to PubMed...
  7. American Thoracic Society, Infectious Diseases Society of America. (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416. doi: 10.1164/rccm.200405-644ST. Go to original source...
  8. Standard iniciální antibiotické terapie HAP ve FN Olomouc. https://altus.fnol.loc/Default.aspx?page=p831750607 Směrnice č. Sm-L034.
  9. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org.
  10. Burgmann H, Hiesmayr JM, Savey A, et al. Impact of nosocomial infections on clinical outcome and resource consumption in critically ill patients. Intensive Care Med, 2010; 36(9): 1597-1601. Go to original source... Go to PubMed...
  11. Pravin Charles MV, Easow JM., Joseph NM, et al. Role of Appropriate Therapy in Combating Mortality among the Ventilated Patients. J Clin. Diagn. Res., 2014; 8(8): DC01-DC03. Go to original source... Go to PubMed...
  12. Chung, RD, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. American Journal of Respiratory and Critical Care Medicine, 2011; 184(12), 1409-1417. Go to original source... Go to PubMed...
  13. Forel JM, Voillet F, Pulina D, et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung-protective strategy. Crit Care, 2012; 16(2): 65. Go to original source...
  14. Valle's J, Martin-Loeches I, Torres A. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med, 2014; 40: 572-581. Go to original source...
  15. Ioanas M, Cavalcanti M, Ferrer M. Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines. Eur Respir J, 2003; 22: 876-882. Go to original source... Go to PubMed...
  16. Luna CM, Aruj P, Niederman MS, et al. Grupo Argentino de Estudio de la Pneumonia Asociada el Respirador group. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J., 2006; 27: 158-164. Go to original source... Go to PubMed...
  17. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated pneumonia. Am J Respir Crit Care Med, 2005; 171: 388-416. Go to original source...
  18. Masterton R, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial chemotherapy J Antimicrob Chemother. 2008. Go to original source... Go to PubMed...
  19. Dalhoff K, Abele-Horn M, Andreas S, et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie, 2012; 66(12): 707-765. Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.